AXSOME THERAPEUTICS Meloxicam Patent US12611413B2
Summary
AXSOME THERAPEUTICS INC. has been granted US Patent 12611413B2 covering pharmaceutical compositions comprising meloxicam in combination with cyclodextrin and/or carbonate or bicarbonate, filed July 8 2025 and granted April 28 2026. The patent relates to compositions that improve bioavailability and pharmacokinetics of meloxicam for treating pain conditions including migraine and arthritis, with 26 total claims. This represents a new enforceable patent grant conferring exclusive rights to the patented compositions and methods.
“Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO granted US Patent 12611413B2 to AXSOME THERAPEUTICS INC. covering pharmaceutical compositions comprising meloxicam combined with cyclodextrin and/or a carbonate or bicarbonate. The patent includes 26 claims relating to improved NSAID bioavailability and pharmacokinetics for pain treatment including migraine. The composition is designed to achieve a Tmax of meloxicam of 3 hours or less.
Pharmaceutical companies developing meloxicam formulations or combination therapies for migraine or pain treatment should review this patent for potential licensing needs or design-around considerations. Freedom-to-operate analyses for meloxicam-based products may be affected by this newly granted intellectual property.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Pharmaceutical compositions comprising meloxicam
Grant US12611413B2 Kind: B2 Apr 28, 2026
Assignee
AXSOME THERAPEUTICS, INC.
Inventors
Herriot Tabuteau
Abstract
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
CPC Classifications
A61K 31/5415 A61K 31/4196 A61P 25/06
Filing Date
2025-07-08
Application No.
19263324
Claims
26
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.